PubRank

Pierre Pacaud

Author PubWeight™ 37.82‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Rho kinases in cardiovascular physiology and pathophysiology. Circ Res 2006 2.97
2 The Rho exchange factor Arhgef1 mediates the effects of angiotensin II on vascular tone and blood pressure. Nat Med 2010 1.84
3 RhoA expression is controlled by nitric oxide through cGMP-dependent protein kinase activation. J Biol Chem 2003 1.35
4 RhoA and Rho kinase activation in human pulmonary hypertension: role of 5-HT signaling. Am J Respir Crit Care Med 2009 1.28
5 Transglutaminase-dependent RhoA activation and depletion by serotonin in vascular smooth muscle cells. J Biol Chem 2006 1.27
6 Phosphorylation of serine 188 protects RhoA from ubiquitin/proteasome-mediated degradation in vascular smooth muscle cells. Circ Res 2005 1.24
7 Inhibition of RhoA/Rho kinase pathway is involved in the beneficial effect of sildenafil on pulmonary hypertension. Br J Pharmacol 2005 1.24
8 The role of Rho protein signaling in hypertension. Nat Rev Cardiol 2010 1.23
9 Rho kinase blockade prevents inflammation via nuclear factor kappa B inhibition: evidence in Crohn's disease and experimental colitis. Gastroenterology 2003 1.21
10 Ste20-related kinase SLK phosphorylates Ser188 of RhoA to induce vasodilation in response to angiotensin II Type 2 receptor activation. Circ Res 2008 1.05
11 Hyaluronan induces vascular smooth muscle cell migration through RHAMM-mediated PI3K-dependent Rac activation. Cardiovasc Res 2006 1.04
12 RhoA activation and interaction with Caveolin-1 are critical for pressure-induced myogenic tone in rat mesenteric resistance arteries. Cardiovasc Res 2006 1.04
13 Angiotensin II induces RhoA activation through SHP2-dependent dephosphorylation of the RhoGAP p190A in vascular smooth muscle cells. Am J Physiol Cell Physiol 2009 1.03
14 Small G proteins in the cardiovascular system: physiological and pathological aspects. Physiol Rev 2013 0.97
15 Regulation of Rho proteins by phosphorylation in the cardiovascular system. Trends Cardiovasc Med 2006 0.94
16 Effects of HIV protease inhibitors on progression of monocrotaline- and hypoxia-induced pulmonary hypertension in rats. Circulation 2010 0.93
17 Urotensin II is a new chemotactic factor for UT receptor-expressing monocytes. J Immunol 2007 0.91
18 Structure-activity relationships and structural conformation of a novel urotensin II-related peptide. Peptides 2004 0.90
19 RhoA phosphorylation induces Rac1 release from guanine dissociation inhibitor alpha and stimulation of vascular smooth muscle cell migration. Mol Cell Biol 2010 0.90
20 AMPK alpha 1-induced RhoA phosphorylation mediates vasoprotective effect of estradiol. Arterioscler Thromb Vasc Biol 2011 0.90
21 Rho exchange factors in the cardiovascular system. Curr Opin Pharmacol 2008 0.89
22 The Rho protein exchange factor Vav3 regulates vascular smooth muscle cell proliferation and migration. Cardiovasc Res 2009 0.86
23 RhoA and resistance artery remodeling. Am J Physiol Heart Circ Physiol 2005 0.86
24 Stent implantation activates RhoA in human arteries: inhibitory effect of rapamycin. J Vasc Res 2004 0.85
25 Sildenafil prevents change in RhoA expression induced by chronic hypoxia in rat pulmonary artery. Circ Res 2003 0.83
26 Drug-eluting stents in bifurcations: bench study of strut deformation and coating lesions. Circ Cardiovasc Interv 2010 0.83
27 Identification of differentially expressed genes in human varicose veins: involvement of matrix gla protein in extracellular matrix remodeling. J Vasc Res 2007 0.83
28 Regulation of Rho signaling pathways in interleukin-2-stimulated human T-lymphocytes. FASEB J 2005 0.83
29 Structure-activity relationships of urotensin II and URP. Peptides 2007 0.83
30 Role of Rho kinase signalling in healthy and varicose human saphenous veins. Br J Pharmacol 2002 0.82
31 Urotensin II and atherosclerosis. Peptides 2007 0.81
32 RhoA guanine exchange factor expression profile in arteries: evidence for a Rho kinase-dependent negative feedback in angiotensin II-dependent hypertension. Am J Physiol Cell Physiol 2012 0.80
33 Structure-activity relationships of human urotensin II and related analogues on rat aortic ring contraction. J Enzyme Inhib Med Chem 2003 0.80
34 Involvement of Rho GTPases and their regulators in the pathogenesis of hypertension. Small GTPases 2014 0.79
35 Structure-activity relationships of a novel series of urotensin II analogues: identification of a urotensin II antagonist. J Med Chem 2006 0.78
36 Direct stenting limits sirolimus-eluting stent edge neointimal thickening. J Vasc Surg 2007 0.76
37 Rho-kinase inhibitors: pharmacomodulations on the lead compound Y-32885. J Enzyme Inhib Med Chem 2002 0.76
38 [The cardiovascular research: towards a new integrative model of research and care]. Med Sci (Paris) 2008 0.75
39 [The exchange factor Arhgef1: a new target in hypertension]. Med Sci (Paris) 2010 0.75
40 [Activation of G-proteins in three dimensions: one step toward the therapeutic inhibition of nucleotide exchange factors]. Med Sci (Paris) 2004 0.75
41 Synthesis and pharmacological study of Rho-kinase inhibitors: pharmacomodulations on the lead compound Fasudil. J Enzyme Inhib Med Chem 2003 0.75